Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
y we'll have to re-scan them and follow up, potentially stop drug and or uh halt it completely if those uh uh micro hemorrhages and microedema don't clear.
So this is not a a drug you just give it to someone and you know see them back in six months.
Early on it requires frequent MRIs and based on those results even more frequent andor stopping
the drug and and I I I would take that extremely seriously.
Yeah.
wonderful.
Yeah, I know.
I advocate uh biogen set of bars so low that uh anything a drug company d other drug company does is automatically virtuous behavior.
Uh but you know, um I can't tell you how when you chat with the folks in pharma how much they just roll their eyes at how what biogen did.
The fr the the challenge I think we face when we think about the need for diversity in clinical trials is diversity with respect to what for what reason.
If it's with respect to the um reducing the risk of developing disease and or having disease progression, 'cause these people have already developed the disease in the clarity study, it's about progression.
Then I'd want us to make sure that your design is gonna
Attend to what you think are those
mechanistic factors that might have persons say who self identify as African American progressing faster.
I I didn't see that going on in this study.
Instead I saw diversity with respect to just equity issues of access to clinical trials, right?
You know, that that that all Americans should have access to a trial assuming they meet the criteria for entry.
And it's odd when you as a case with Adecetemap that there were you know, you could count on one hand the number of persons of color in the study.
And there I think there are two very dissociable issues in in with respect to qu diversity in clinical trials.
The former actually is very scientifically challenging because if you think about writing a label
Showing 701–720 of 1,378 · page 36 of 69
← Previous
Next →